OBJECTIVES: The aim of this open label, multicentric study was to evaluate the corticosteroid-sparing effect of an emollient milk containing Oat Rhealba® extracts on quality of life of family in a group of infants aged less than 1- year old with Atopic Dermatitis (AD). METHODS: Children with mild to moderate AD (SCORAD index = 20 and = 70) were randomised in two parallel groups: a group with the emollient milk applied twice daily, and a group receiving no emollient. The use of topical corticoids (class II & III non-fluorinated desonide corticoids) was allowed in the event of inflammatory flare-ups in both groups. The primary end point was measurement of the total amount of topical steroids used (grammes) at six weeks. The secondary end points were, clinical rating changes (SCORAD index), and Quality of Life (QoL) using DFI scale. The DFI scale (Dermatitis Family Impact questionnaire) was completed by the parents and aimed at measuring the impact of dermatosis on the quality of life of children affected and their family. RESULTS: DFI total score and all its dimensions were comparable upon inclusion between treated and non treated groups (total score: 5.30 (5.23) versus 6.42 (5.32) respectively). Improvement was noted for both groups. A significant improvement was only noted in the treated group for the items about sleep (In the past seven days, has the child's eczema had any effect on the sleep of other family members?) and about consequences (In the past seven days, has your participation in the child's treatment had any consequence on your life ?). CONCLUSION: After six weeks of treatment, we noted in the parents of the treated group a significant improvement in sleep due to treatment impact and a reduced treatment impact on daily life.